Contingency Management + Cognitive Behavioral Therapy for Quitting Vaping

Recruiting in Palo Alto (17 mi)

Overseen by Suchitra Krishnan-Sarin, PhD

Age: < 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Yale University

Trial Summary

What is the purpose of this trial?

This trial aims to help teenagers who vape quit by using rewards and online counseling. The program targets teens aged 13-19 who want to stop vaping. It works by giving rewards for not vaping and providing counseling to change their behavior and thoughts about vaping.

Research Team

Suchitra Krishnan-Sarin, PhD

Principal Investigator

Yale University

Eligibility Criteria

This trial is for high school students aged 13-19 who regularly use e-cigarettes with nicotine and want to quit. They must be able to read and write, have no major mental health issues untreated, not use psychoactive drugs or antidepressants unless stable and monitored, not pregnant or lactating, and without substance dependence except mild cannabis use.

Inclusion Criteria

I use e-cigarettes regularly and want to quit.

Able to read and write

Does not meeting criteria for dependence on other psychoactive substances, psychosis, major depression or panic disorder based on psychological evaluation.

Exclusion Criteria

I do not have psychosis or a high risk of harming myself or others.

I've been on stable doses of my mental health meds for over 2 months.

Currently enrolled in, or planning to enroll in any other behavioral or pharmacological treatments for cessation of nicotine or vaping

Treatment Details

Interventions

• Control (Other)
• Remote Contingency Management (CM) for nicotine abstinence (Behavioral Intervention)

Trial Overview The study tests a new program combining rewards (contingency management) with online video counseling (cognitive behavioral therapy) to help teenagers stop vaping. Participants will either receive this intervention or be in a control group that does not receive the treatment.

Participant Groups

Group I: Remote Contingency Management (CM) for nicotine abstinence Experimental Treatment 1 Intervention

Participants will be paid increasing amounts of payment for each negative saliva cotinine test.

Group II: Control Placebo Group 1 Intervention

Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials

1,963

Recruited

3,046,000+

Nancy J. Brown

Yale University

Chief Medical Officer since 2020

MD from Yale School of Medicine

Peter Salovey

Yale University

Chief Executive Officer since 2013

PhD in Psychology from Yale University

American Heart Association

Collaborator

Trials

352

Recruited

6,196,000+

Eduardo Sanchez

American Heart Association

Chief Medical Officer since 2013

MD from University of Texas Southwestern Medical School, MPH from UT Health Science Center at Houston, MS in Biomedical Engineering from Duke University

Katrina McGhee

American Heart Association

Chief Executive Officer since 2020

MBA from the University of Texas at Arlington